UNGA 2024 and the AMR HLM:
Pre-Meeting Reports and Post-Meeting Notes
The HLM has now happened, but I am going to keep this webpage going (at least for now) as it is useful repository. Helpful post-HLM materials include the following:
- The 1 Oct 2024 newsletter for my review of the events at the HLM.
- CDC’s post-UNGA blog post (also available as a .pdf of their nearly identical 4 Oct 2024 post-UNGA summary email). CDC’s summary provides informative highlights from several AMR-related side-meetings.
- WHO’s 4 Oct 2024 AMR email summary. In addition to just being a good tour of WHO’s diverse array of activities, it starts with a quick overview of the HLM and then points to next steps (e.g., the November 2024 Ministerial meeting in Saudi Arabia).
- An excellent 9 Oct 2024 blog post from Ramanan Laxminarayan’s One Health Trust that provides a very detailed summaries of several of the side events. Lots of photos, lots of summarized commentary … really gives a good sense of the meetings.
During the run-up to the HLM (High-Level Meeting) on AMR during UNGA 2024 (the UN General Assembly, September 2024, see the 15 Apr 2023 newsletter for details), I thought it would be useful to have a list of major reports that had been released to inform those discussions. I am sure I am going to miss things (at least initially), so please drop me a note (john.rex@amr.solutions) if you want to see something added to this list. Thanks, —jr
- Reports (mostly) Focused on AMR related to human health
- Manufacturing
- 05 Jun 2023: Antibiotic Manufacturing Certification
- The AMR Industry Alliance has worked with BSI Standards to develop a certification process for safe discharge during antibiotic manufacturing.
- Press release, website, 25 Sep 2023 newsletter
- 05 Jun 2023: Antibiotic Manufacturing Certification
- Stewardship and Access
- 22 Mar 2021: Stewardship & Access Guide
- From CARB-X, Wellcome, And Partners, this is the definitive guide
- The 22 Mar 2021 newsletter is the best starting point; it also includes a video chat about the new guidelines
- Feb 2024: Equitable & Responsible Access Roadmap
- The AMR Industry Alliance‘s roadmap covers diagnostics, drugs, and procurement.
- The document itself
- 22 Mar 2021: Stewardship & Access Guide
- R&D: Push, Pull, People, and Evidence for Action
- 07 Sep 2023: Overcoming Resistance
- This one could have been subtitled “How Canada should Pull for new antibiotics”!
- Webpage, report, one-pager on the report, short slide deck, and 8 Sep 2023 newsletter.
- Report author: Canadian Council of Academies (CCA)
- 21 Sep 2023: A New Grand Bargain to Improve the Antimicrobial Market for Human Health
- Tackles the question of “Why would any given group take action to support an antibiotic ecosystem?” from the perspective of High-Income Countries (HICs), Low- and Middle-Income Countries (LMICs), Pharmaceutical companies, and International Organizations.
- Webpage, report, and 5 Nov 2023 newsletter.
- Report author: Center for Global Development (CGD)
- 15 Nov 2023: Value and sustainability of antibiotics as essential tools for the healthcare system and people’s health
- This one could have been subtitled “How Italy should Push and Pull as it takes the 2024 G7 chair“!
- Webpage, full report (in Italian), press release (in English), one-page policy brief (in English), and 7 Dec 2023 newsletter.
- Report author: The European House – Ambrosetti
- 08 Feb 2014: Leaving the Lab: Tracking the Decline in AMR R&D Professionals
- As you can infer from this title, this one summarizes the alarming multi-year decline in the number of active AMR R&D professionals.
- Press release, report, and 8 Feb 2024 newsletter.
- 15 Feb 2024: 2024 AMR Preparedness Index Progress Report
- Updates a 2021 survey on progress on National Action Plans, Push-Pull, Access, Appropriate Use, and Environmental Protection by 11 countries (Brazil, Canada, China, France, Germany, India, Italy, Japan, South Korea, UK, US).
- Press release, report, and 15 Feb 2024 newsletter.
- Report authors: Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA)
- 22 Feb 2024: The Economics of Antibiotic Resistance
- A superb tour of way an economist (and hence a Finance Minister) would view AMR as a Market Failure
- Webpage, paper, blog, and 28 Feb 2024 newsletter
- Report authors: For the Center for Global Development (CGD), Anthony McDonnell, Ranil Dissanayake, Katherine Klemperer, Flavio Toxvaerd, and Michael Sharland
- 25 Mar 2024: Effective antibiotics for the Swiss health care system: today and in the future
- This one could have been subtitled “How Switzerland should Push and Pull“!
- Webpage, primary report, and 5 April 2024 newsletter
- Report author: Swiss Roundtable on Antibiotics
- 3 Apr 2024: Towards Specific Commitments and Action in the Response to Antimicrobial Resistance
- Yes, it’s a long title! And, there is a subtitle: Recommendations for consideration by UN Member States in the outcome document of the High-level Meeting on AMR in September 2024
- Webpage, report, and 19 Apr 2024 newsletter
- There is also an important economic study that is used as supportive evidence. It is hard to find, but I do have this link: https://www.amrleaders.org/resources/m/item/annex-to-the-glg-report
- Report author: GLG AMR (Global Leaders Group on Antimicrobial Resistance)
- 23 May 2024: The Lancet Series on Antimicrobial Resistance: The need for sustainable access to effective antibiotics
- A superb collection of papers covering the ideas of (i) Sustainable (ii) Access to (iii) Effective Antibiotics. Look closely at those 3 words: such a good summary … it’s a deep read, but well worth your time!
- Webpage, 23 May 2024 newsletter, Fireside Chat with Ramanan Laxminarayan about the series and its messages
- 12 Aug 2024: UK Subscription model goes live!
- OK, it’s not a report per se but if it were it would be called “Here’s what can be done!”
- The UK Subscription model really does set the pace for the rest of the world to follow
- Webpage, 19 Aug 2024 newsletter
- Aug 2024: Antibacterial pipeline trends and recommendations to enhance research and development
- This policy brief does a good job of briefly (!) outlining 7 key points: the weak pipeline, the issues faced by developers, specific therapeutic gaps, the oral drug gap, the pediatric drug gap, the LMIC gap, and the non-traditional gap
- Webpage, report, 1 Sep 2024 newsletter
- Report author: WHO
- 17 Sep 2024: Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
- The team behind the Global Burden of Disease (GBD) project brings us the sobering news that AMR will kill 39m during 2025-2050 unless we act!
- Link to article and to the 17 Sep 2024 newsletter
- Report author: GBD 2021 Antimicrobial Resistance Collaborators
- 27 Sep 2024: Forecasting the Fallout from AMR: Economic Impacts of Antimicrobial Resistance in Humans
- This paper makes the economic case for action and can be summarized as “Without action, AMR costs go from $66b/yr to $159b/yr by 2050.” The deep economics are not often analyzed — this paper does a great job of articulating the “pay now or pay later” perspective.
- Article itself and to the 27 Sep 2024 newsletter
- Report author: Center for Global Development
- 07 Sep 2023: Overcoming Resistance
- Reports (mostly) focused on agriculture and food chain
- January 2024: Tackling Antimicrobial Resistance in Food and Agriculture
- A global survey of actions being taken by the Quadripartite, the Global Leaders Group, and the various National Action Plans on AMR in agricultural and food systems.
- Webpage, report, and 27 Jan 2024 newsletter.
- Report author: FAO
- About the AMR HLM (High-Level Meeting)
- 23 Jan 2024: Resolution to support an HLM on AMR
- 2 Feb 2024: Letter from the President of the General Assembly announcing the HLM
During the run-up to UNGA 2024 and the HLM on AMR (15 Apr 2023 newsletter for details), I thought it would be useful to have a list of major reports. I am sure I am going to miss things (at least initially), so please drop me a note (john.rex@13.43.35.2) if you want to see something added to this list.
Share
Vivli: Access to Industry’s Susceptibility Surveillance data
Dear All (and with thanks to Patricia Bradford for leading on this newsletter), Did you know you can access raw datasets of antimicrobial susceptibility surveillance data that have been generated by the pharmaceutical industry? Indeed such datasets exist and we’d like to ensure everyone is aware of their availability and potential! Background: The 20 Oct
Italy funds CARB-X and announces pull incentive!
Dear All (and with thanks to Damiano for co-authoring), We have exciting news from the G7 Health Ministers’ Meeting, which was held in person in Ancona on 9-11 October 2024, and the accompanying G7 Joint Finance and Health Ministers’ Meeting, which took place in a hybrid format on 10 October 2024. At the press conference closing
Plazomicin (Achaogen) financial post-mortem: #PassPASTEUR
Dear All (and with thanks to Kevin for co-authoring and also a wonkish alert … get your coffee and settle in for the details), If you’ve been around the antibiotic ecosystem for a while, you’ve hopefully heard the story of the 2019 bankruptcy of Achaogen and the subsequent loss to the entire world of its
EPA (part 5): Interagency Framework on AMR Risks of Antibacterial and Antifungal Pesticides
This is the fifth of a 5-part newsletter series. There is an initial 27 Sep 2023 newsletter introducing the EPA concept note, a second (28 Sep 2023) newsletter that expands on the EPA concept note, a third (12 Jan 2024) newsletter about ending the use of streptomycin spray on citrus crops, and a 4th newsletter (27 Jan 2024) containing some additional resources. Dear All, Excitingly, the US EPA